Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort.

Autor: Schmid S; Department of Oncology and Haematology, Cantonal Hospital St. Gallen, 9007, St. Gallen, Switzerland. sabine.schmid@kssg.ch.; Lung Unit, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada. sabine.schmid@kssg.ch., Mauti LA; Department of Oncology and Haematology, Cantonal Hospital St. Gallen, 9007, St. Gallen, Switzerland., Friedlaender A; Oncologie, Hôpitaux universitaires de Genève, Geneva, Switzerland., Blum V; Department of Oncology, Cantonal Hospital Lucerne, Lucerne, Switzerland., Rothschild SI; Department of Oncology, University Hospital Basel, Basel, Switzerland., Bouchaab H; Oncologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland., Frösch P; Istituto Oncologico della Svizzera Italiana, Ospedale Regionale di Bellinzona e Valli, Bellinzona, Switzerland., Britschgi C; Department of Medical Oncology and Hematology, University Hospital Zurich, Comprehensive Cancer Center Zurich, University of Zurich, Zurich, Switzerland., König D; Department of Oncology, Cantonal Hospital Winterthur, Winterthur, Switzerland., Wannesson L; Istituto Oncologico della Svizzera Italiana, Ospedale Regionale di Bellinzona e Valli, Bellinzona, Switzerland., Janthur WD; Department of Oncology, Cantonal Hospital Aarau, Aarau, Switzerland., Schär S; SAKK, Swiss Group for Clinical Cancer Research, Coordinating Center, Bern, Switzerland., Demmer I; Institute of Pathology, Cantonal Hospital St. Gallen, 9007, St. Gallen, Switzerland., Addeo A; Oncologie, Hôpitaux universitaires de Genève, Geneva, Switzerland., Jochum W; Institute of Pathology, Cantonal Hospital St. Gallen, 9007, St. Gallen, Switzerland., Früh M; Department of Oncology and Haematology, Cantonal Hospital St. Gallen, 9007, St. Gallen, Switzerland.; University of Bern, Bern, Switzerland.
Jazyk: angličtina
Zdroj: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2020 Aug; Vol. 69 (8), pp. 1605-1613. Date of Electronic Publication: 2020 Apr 19.
DOI: 10.1007/s00262-020-02565-0
Abstrakt: Objectives: Early clinical trials showed promising outcomes with immune-checkpoint inhibitors (ICI) in a subset of patients with relapsed small-cell lung carcinoma (SCLC). The aim of this retrospective analysis was to assess the efficacy and safety of ICI for relapsed SCLC in a real-world patient population.
Methods: Nine cancer centres in Switzerland contributed data to this cohort. Responses were assessed by the local investigators using standard RECIST v1.1 criteria. Progression-free survival (PFS) and overall survival (OS) were analysed by the Kaplan-Meier method. Associations between potential predictive markers and survival endpoints were probed by Cox proportional hazards.
Results: Forty-five patients were included in the analysis. Median age was 63 years, 73% were males and 18% had an ECOG performance status (PS) ≥ 2. ICIs were given as second-line treatment in 60%. Twenty-four patients (53%) received ipilimumab with nivolumab. Twenty-eight patients (62%) had undergone irradiation (RT) prior to or during ICI. Overall response rate (ORR) was 29% and median PFS and OS were 2.3 and 6.5 months, respectively. Median duration of response was 9 months (95% CI 2.8-NA). Five patients maintained their response for > 6 months, all of them receiving combination treatment. There were no new safety signals.
Conclusion: This is the first report of "real-world" data on ICI in relapsed SCLC also including patients with poor PS. Promising durable responses were observed. No biological prognostic marker could be identified.
Databáze: MEDLINE
Externí odkaz: